La cadena de opciones muestra datos clave de las opciones de acciones de Dogwood Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Dogwood Therapeutics..

Dogwood Therapeutics (NASDAQ:DWTX) Bolsa, Cadena de Opciones

Dogwood Therapeutics

Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics Inc

Earnings

News

DHAI

DIH Holding US Q2 EPS $(0.01) Up From $(0.10) YoY, Sales $18.2M Up From $13.1M YoY

Fundamental Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) reported quarterly earnings of $15.06 per share. This is a 288.01 percent increase over losses of $(8.01) per share from the same period last year. The company reported $10.45 million in sales this quarter. This is a 155.82 percent increase over sales of $4.09 million the same period last year.

Fundamental Global Q3 EPS $15.06 Up From $(8.01) YoY, Sales $10.45M Up From $4.09M YoY

flyExclusive (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#AMEX">FLYX</a>) reported quarterly losses of $(0.32) per share. The company reported $76.92 million in sales this quarter. This is a 24.02 percent increase over sales of $62.03 million the same period last year.

FLYX

flyExclusive Q3 EPS $(0.32), Sales $76.92M Up From $62.03M YoY

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $7 price target.

Price Target

Analyst Ratings

PASG

Chardan Capital Maintains Buy on Passage Bio, Maintains $7 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

General

CDXS

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) reported quarterly losses of $(1.54) per share which beat the analyst consensus estimate of $(4.14) by 62.8 percent.

Earnings Beats

PHIO

Phio Pharma Q3 2024 GAAP EPS $(1.54) May Not Be Comparable To $(4.14) Estimate

Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

AIEV

Thunder Power Holdings Q3 EPS $(0.02), Same YoY

Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(0.94) by 104.26 percent. This is a 139.51 percent decrease over earnings of $4.86 per share from the same period last year.

Earnings Misses

ATXI

Avenue Therapeutics Q3 EPS $(1.92) Misses $(0.94) Estimate

Legal

GREE

Greenidge Says New York Supreme Court Judge Rejected Department Of Environmental Conservation's Action To Deny Its Application For Renewal Of Title V Air Permit

Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.80) by 5 percent. This is a 14.61 percent increase over losses of $(0.89) per share from the same period last year.

AQMS

Aqua Metals Q3 EPS $(0.76) Beats $(0.80) Estimate

President-elect Donald Trump's nomination of former Democratic Congresswoman <a href="https://www.benzinga.com/topic/tulsi-gabbard">Tulsi Gabbard</a> as Director of National Intelligence (DNI) has sparked debate.
The selection drew mixed reactions due to her unconventional political background and history of controversial statements. Though, the <a href="https://www.benzinga.com/markets/cannabis/23/02/30743988/breaking-the-chains-of-cannabis-criminalization-tulsi-gabbards-fight-for-legalization-from-grine">cannabis industry isn&#8217;t complaining.</a>
If confirmed, Gabbard would become the highest-ranking intelligence official despite a lack of experience within the intelligence community. Her appointment marks a sharp departure from past presidential selections, as she has never served on a congressional intelligence committee.
A former Hawaii Army National Guard member who deployed to Iraq with a medical unit, Gabbard has frequently criticized U.S. foreign policy as overly aggressive and imperialistic. 
Her outspoken stances, including opposition to mainstream U.S. intelligence views on Russia, raise questions about how she will navigate her role overseeing the nation's 18 intelligence agencies with a combined budget of approximately $70 billion.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41982165/new-gop-senate-leader-john-thune-opposes-marijuana-legalization-implications-for-banking-access-and-more">New GOP Senate Leader John Thune Opposes Marijuana Legalization: Implications For Banking Access And More</a>
<h3 class="wp-block-heading">Cannabis Policy Contributions</h3>
Beyond foreign policy, Gabbard's legislative record includes notable contributions to cannabis reform, earning her broad support within the marijuana industry and advocacy groups. Over her eight years in Congress, she was as a vocal supporter of marijuana and hemp reform, introducing legislation that reflected her commitment to decriminalization and medicinal use.
In 2017, Gabbard introduced a bipartisan bill that sought to end federal prohibition by removing cannabis from the Controlled Substances Act, a landmark move that appealed to both sides of the aisle.
"Our archaic and outdated marijuana laws are turning everyday Americans into criminals," Gabbard <a href="https://norml.org/blog/2019/03/07/rep-tulsi-gabbard-i-just-introduced-legislation-to-end-the-federal-marijuana-prohibition/">said</a> at the time. "Every day, the economic and social impacts of marijuana prohibition are having devastating effects on communities across the country." 
Her advocacy extended to military service members. In 2020, she <a href="https://www.benzinga.com/markets/cannabis/20/07/16709095/congress-allows-troops-to-use-cbd-products-1">filed an amendment</a> to permit the use of hemp-derived CBD products, pushing back against the expanding ban on these products within the armed forces and Veterans Administration (VA).
<h3 class="wp-block-heading">Russia Propagandist? </h3>
Despite her legislative achievements and progressive stance on cannabis reform, Gabbard's alignment with the intelligence community's stance on Russia remains contentious. In recent years, she faced backlash from lawmakers who accused her of amplifying Russian propaganda after she shared a video referencing alleged U.S.-funded "bio labs" in Ukraine. The claim was widely debunked by U.S., Ukrainian officials and independent sources.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There are 25+ US-funded biolabs in Ukraine which if breached would release &amp; spread deadly pathogens to US/world. We must take action now to prevent disaster. US/Russia/Ukraine/NATO/UN/EU must implement a ceasefire now around these labs until they're secured &amp; pathogens destroyed <a href="https://t.co/dhDTH5smIG">pic.twitter.com/dhDTH5smIG</a>
&mdash; Tulsi Gabbard &#x1f33a; (@TulsiGabbard) <a href="https://twitter.com/TulsiGabbard/status/1502960938147729413?ref_src=twsrc%5Etfw">March 13, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41992074/trump-says-his-secretary-of-state-pick-marco-rubio-is-powerful-voice-for-freedom-but-what-about-cannabis">Trump Says His Secretary Of State Pick Marco Rubio Is &#8216;Powerful Voice For Freedom&#8217; – But What About Cannabis?</a></li>
</ul>
Photo: <a href="https://www.flickr.com/people/22007612@N05">Gage Skidmore</a>, <a href="https://en.wikipedia.org/wiki/en:Creative_Commons">Creative Commons</a>&nbsp;<a href="https://creativecommons.org/licenses/by-sa/2.0/deed.en">Attribution-Share Alike 2.0</a>/Wikipedia

Cannabis

Government

Politics

Trump's National Intelligence Pick Is Cannabis Advocate Tulsi Gabbard: Critics Say Former Congresswoman Parrots Russia Propaganda

AIFF

Firefly Neuroscience Reports  Cash Of $1.2M As Of September 30, 2024

DA Davidson analyst Linda Bolton Weiser maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and maintains $16 price target.

FNKO

DA Davidson Maintains Buy on Funko, Maintains $16 Price Target

Outlook
<ul>
<li>The Company anticipates Net Income will be approximately ($0.7) million in Q4 2024 and approximately ($0.7) million in Q1 2025, representing substantial increases driven by a reduction in operating and interest expenses due to the recently announced $28.8 million debt restructuring and $13.5 million Net Income Improvement initiative.</li>
<li>The Company anticipates Adjusted EBITDA to be approximately ($1.4) million in Q4 2024, and approximately ($1.1) million in Q1 2025, representing substantially improved runway and progress towards profitability and positive cash-flow.</li>
</ul>
"It is hard to overstate how important the third quarter of 2024 was for Banzai," said Joe Davy, Founder and CEO of Banzai. "We believe this marks a turning point for the Company in many ways. Banzai achieved&nbsp;a 31% annualized&nbsp;Annual Recurring Revenue&nbsp;growth&nbsp;rate&nbsp;and a historic record for Net Revenue Retention. We also made game-changing improvements to our balance sheet and cost structure to set us up for sustainable profitability in the future. Growth was driven by our focus on the Reach product through re-engineering and expanded sales efforts, leading to the addition of 1,785 customers through October 2024. In total, we now serve nearly 3,000 customers that have contributed to top and bottom-line sequential improvements from the second quarter.
"To better serve our customers, we have continued to invest in our software platforms and growth. We've launched a new product, Curate, to bring AI-powered newsletters that leverage OpenAI's GPT-4o to automate the newsletter creation process by writing relevant, branded articles that resonate with target audiences. We added significant enhancements to our Demio platform through deeper integration with Salesforce, the industry leading AI CRM company, with key enhancements designed to maximize efficiency and insight, offering marketers a more scalable, data-rich experience. We also released a major improvement to the Demio HubSpot integration. This upgrade offers unparalleled flexibility and efficiency in managing webinar data, empowering marketers to streamline their webinar management and marketing efforts, leading to better decision-making and higher ROI.
"Alongside a $5.0 million private placement transaction and debt restructuring transactions we executed, we implemented a strategic initiative that we expect will enable us to significantly improve net income, substantially extend our cash runway and invest in growth. We are making significant progress on these goals and overall improvement in net income is expected to be approximately $12.2 million annually when fully implemented, while maintaining our growth outlook.
"Looking ahead, our ability to leverage deep analytics and insights to drive marketing decisions combined with leveraging AI to launch exciting new products and capabilities, will continue to drive growth. We will continue to manage costs efficiently while investing in our software platform, sales and marketing and product development. We look forward to additional updates on our anticipated milestones in the weeks and months to come," concluded Davy.
 &nbsp;

Guidance

BNZI

Banzai Anticipates Net Income Will Be ~($0.7M) In Q4 2024 And ~($0.7M) In Q1 2025, Representing Substantial Increases Driven By A Reduction In Operating And Interest Expenses Due To The Recently Announced $28.8M Debt Restructuring And $13.5M Net Income Improvement Initiative; Adjusted EBITDA To Be ~($1.4M) In Q4 2024, And ~($1.1M) In Q1 2025, Representing Substantially Improved Runway And Progress Towards Profitability And Positive Cash-Flow

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported financial results for the third quarter Thursday after the bell. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41990105/ast-spacemobile-provides-business-update-and-third-quarter-2024-results">key details from the report</a>.
Q3 Earnings:&nbsp;AST SpaceMobile&nbsp;reported&nbsp;third-quarter revenue of $1.1 million. The company reported an adjusted loss of $1.10 per share, missing&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;for a loss of 20 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Operating expenses for the&nbsp;third quarter&nbsp;totaled&nbsp;$66.6 million, up $2.7 million from the second quarter. The company ended the period with $518.9 million in cash, cash equivalents and restricted cash. 
&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said Abel Avellan, founder, chairman and CEO of AST SpaceMobile. 
&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;
AST SpaceMobile executives will hold a conference call at 5 p.m. ET to further discuss the quarter with investors.
See Also: <a href="https://www.benzinga.com/general/space/24/11/41961309/rocket-lab-ceo-touts-spacex-rival-status-trump-impact-on-space-as-stock-surges-almost-30">Rocket Lab CEO Touts SpaceX Rival Status, Trump Impact On Space As Stock Surges Almost 30%</a>
Service Agreements: AST SpaceMobile separately announced launch services agreements securing the orbital launch capacity to enable continuous space-based cellular broadband service coverage.
The company&#8217;s global service will initially target key markets including the U.S., Europe, Japan and other strategic markets.
The company&#8217;s next-gen Block 2 Bluebird satellites are expected to deliver up to 10 times the bandwidth capacity of the Bluebirds currently in orbit, and are designed to be compatible with all major launch vehicles.
&#8220;With these new launch services agreements, our in-house vertically integrated manufacturing capabilities in Texas, our mobile operator partners, and the additional capital raised during 2024, we are now well-positioned to reach our goal of continuous cellular broadband service coverage, enabling our service to hundreds of millions of users around the world and the U.S. government,&#8221; said Scott Wisniewski, president of AST SpaceMobile.
ASTS Price Action: <a href="http://benzinga.com/quote/asts" target="_blank" rel="noreferrer noopener">AST SpaceMobile shares</a>&nbsp;were down 13.47% after hours, trading at $23.19 at the time of publication Thursday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of AST SpaceMobile.

SPACE

After-Hours Center

Movers

ASTS

AST SpaceMobile Misses Q3 Earnings Expectations, Announces New Launch Service Agreements

Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) reported quarterly losses of $(2.68) per share. This is a 712.12 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $1.08 million which missed the analyst consensus estimate of $1.20 million by 9.95 percent. This is a 2.51 percent decrease over sales of $1.11 million the same period last year.

Banzai International Q3 EPS $(2.68) Down From $(0.33) YoY, Sales $1.08M Miss $1.20M Estimate

FBYD

Falcons Beyond Global Q3 EPS $0.46, Sales $2.07M Up From $1.58M YoY

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and maintains $7 price target.

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) reported quarterly earnings of $0.02 per share. This is a 100.14 percent increase over losses of $(14.15) per share from the same period last year. The company reported $132.00 thousand in sales this quarter. This is a 221.95 percent increase over sales of $41.00 thousand the same period last year.

ADGM

Adagio Medical Holdings Q3 EPS $0.02 Up From $(14.15) YoY, Sales $132.00K Up From $41.00K YoY

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $55 price target.

CRVO

Chardan Capital Maintains Buy on CervoMed, Maintains $55 Price Target

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), retaining the price target of $25.0...

Strategic Merger Positions Dogwood Therapeutics for Success with Promising Pipeline and Financial Stability

Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule

Dogwood (DWTX) Therapeutics has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The ...

Dogwood regains compliance with Nasdaq listing rule

Virios Therapeutics GAAP EPS of -$2.05

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q3 earnings. Here is a breakdown of the information Virios Therapeutics, Inc. presented to i...

Dogwood Therapeutics Reports Q3 2024 Financial Results

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), with a pr...

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

Dogwood Therapeutics Inc (DWTX) has disclosed a new risk, in the Debt & Financing category. Dogwood Therapeutics Inc. faces a significant risk with...

Comments

Dogwood Therapeutics

Dogwood Therapeutics (DWTX) Opciones

Dogwood Therapeutics (NASDAQ:DWTX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL